ATXI · Categories · Form 4

ATXI - SEC Form 4 insider transactions

Avenue Therapeutics Inc. (ATXI) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ATXI

• 148d
  Large owner Fortress Biotech, Inc. was granted 111,209 shares, increasing direct ownership by 34% to 439,733 units (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 427d
  Large owner Fortress Biotech, Inc. was granted 33,724 shares, increasing direct ownership by 11% to 328,524 units (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 547d
  Director Herskowitz Neil sold $46 worth of shares (23 units at $2.00), decreasing direct ownership by 19% to 97 units (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 573d
  Director Kranzler Jay D sold $137 worth of shares (61 units at $2.24), decreasing direct ownership by 10% to 559 units (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 616d
  SEC Form 4 filed by Director Rosenwald Lindsay A Md

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 616d
  SEC Form 4 filed by Director Herskowitz Neil

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 616d
  SEC Form 4 filed by Director Oltmans Curtis Gale

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 616d
  Chief Executive Officer Maclean Alexandra was granted 170,000 shares (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 616d
  SEC Form 4 filed by Director Kranzler Jay D

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 616d
  Interim PFO and COO Jin David was granted 65,000 shares (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 616d
  SEC Form 4 filed by Director Charles Faith L.

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 777d
  Fortress Biotech, Inc. was granted 413,507 shares, increasing direct ownership by 13% to 3,547,393 units (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 882d
  Fortress Biotech, Inc. was granted 2,101,496 shares, increasing direct ownership by 204% to 3,133,886 units (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 903d
  Davidow Robert L sold $86,560 worth of shares (617,000 units at $0.14), decreasing direct ownership by 28% to 681,000 units (SEC Form 4)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 995d
  SEC Form 4: Rosenwald Lindsay A Md bought $251,046 worth of shares (348,675 units at $0.72), increasing direct ownership by 6,179% to 354,318 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 995d
  SEC Form 4: Fortress Biotech, Inc. bought $301,255 worth of shares (418,410 units at $0.72), increasing direct ownership by 68% to 1,032,390 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1064d
  SEC Form 4 filed by Charles Faith L.

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1064d
  SEC Form 4 filed by Jin David

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1064d
  SEC Form 4 filed by Rosenwald Lindsay A Md

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1064d
  SEC Form 4 filed by Kranzler Jay D

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1064d
  SEC Form 4 filed by Oltmans Curtis Gale

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1064d
  SEC Form 4 filed by Herskowitz Neil

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1066d
  SEC Form 4 filed by Maclean Alexandra

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1156d
  SEC Form 4 filed by Fortress Biotech, Inc.

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1246d
  SEC Form 4: Fortress Biotech, Inc. was granted 322,225 shares, increasing direct ownership by 135% to 561,561 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1329d
  SEC Form 4: Invagen Pharmaceuticals, Inc. sold $2,999,882 worth of shares (388,888 units at $7.71), closing all direct ownership in the company

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1625d
  SEC Form 4: Herskowitz Neil was granted 69,020 shares, increasing direct ownership by 60% to 183,744 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1625d
  SEC Form 4: Kranzler Jay D was granted 69,020 shares, increasing direct ownership by 107% to 133,683 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1625d
  SEC Form 4: Oltmans Curtis Gale was granted 49,020 shares

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1626d
  SEC Form 4: Lu Lucy was granted 411,616 shares, increasing direct ownership by 122% to 748,949 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1626d
  SEC Form 4: Vazzano Joseph Walter was granted 100,505 shares, increasing direct ownership by 154% to 165,757 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1722d
  SEC Form 4: Vazzano Joseph Walter sold $11,599 worth of Common Stock (7,160 units at $1.62), decreasing direct ownership by 10% to 65,252 units (withholding tax)

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
• 1853d
  SEC Form 4: Herskowitz Neil bought $9,975 worth of Common Stock (2,500 units at $3.99), increasing direct ownership by 2% to 134,724 units

  4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

Other ATXI categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends